TOTAL: $599.75M
Company (Symbol)# Type Of Financing Number Of Shares, Units Or Warrants (M) Amount Raised (M) Investors; Placement Agents; Details (Date)@

Alnylam Pharmaceuticals Inc. (ALNY) Exercised equity option 0.066 $1.15 Alnylam received $1.15M in cash from partner Novartis AG due to Novartis' decision to exercise its option to purchase 65,922 unregistered Alnylam shares for $17.50 each (5/7)
Amarin Corp. plc (UK; AMRN) Private placement of convertible bridge loan notes N/A $2.6 Amarin raised $2.6M in the placement; the notes mature on June 30 and pay an annual interest rate of 8 percent (5/26)
Array BioPharma Inc. (ARRY) Credit facility extension N/A $40 Array received an additional $40M funding commitment from Deerfield Management, extending the commitment begun in 2008 to $120M (5/20)
Bio-Rad Laboratories Inc. (NYSE:BIO) Private placement of senior subordinated notes N/A $300 Bio-Rad agreed to sell the 8% senior subordinated notes due 2016 (5/20)
BioTime Inc. (OTC BB:BTIM) Private placement of common stock 2.2S and 2.2W $4 BioTime raised $4M through the placement of 2.2M shares and 2.2M warrants (5/14)
Cell Therapeutics Inc. (CTIC) Private placement of common stock and warrants N/A $20 Cell Therapeutics sold $20M in shares at $1.25 each, plus warrants to purchase shares; Rodman & Renshaw LLC acted as exclusive placement agent (5/12)
Cytokinetics Inc. (CYTK) Private placement of common stock 7.1S $14 Cytokinetics raised $14M in an offering of 7.1M shares priced at $1.97 each (5/19)
Cytori Therapeutics Inc. (CYTX) Private placement of stock and warrants 1.86U $4.2 Cytori raised $4.2M through a private placement of 1.86M units, each consisting of one share and 1.75 five-year warants, with an exercise price of $2.62 each (5/8)
Discovery Laboratories Inc. (DSCO) Private placement of common stock and warrants 14S and W $11.3 Discovery Labs raised $11.3M, placing 14M shares and warrants to purchase one-half share of stock for each share of common stock purchased; Lazard Capital Markets LLC acted as exclusive placement agent (5/11)
Generex Biotechnology Corp. (GNBT) Registered direct offering N/A $5 Generex raised $5M through the offering of common stock to select accredited investors at 33 cents per share (5/20)
GenVec Inc. (GNVC) Registered offering 9.6S and W for 9.6S $6 GenVec raised $6M in a registered offering of common stock and warrants (5/28)
Haemacure Corp. (Canada; TSX:HAE) Bridge loan N/A $2.5 Haemacure entered into a term sheet with Angiotech Pharmaceuticals Inc. for a senior secured bridge loan of $2.5M (5/4)
Hemispherx BioPharma Inc. (AMEX:HEB) Private placement of common stock and Series A warrants S and W for 6.1S $18.3 Hemispherx sold the shares for $1.10 each, a 20% discount; Rodman and Renshaw was the exclusive placement agent (5/11)
Hemispherx BioPharma Inc. (AMEX:HEB) Private placement of common stock and warrants 11.9S and W for 4.16S $16 Hemispherx sold $16M in common stock and warrants in a registered offering to two institutional investors (5/19)
Isolagen Inc. (AMEX:ILE) Secured promissory notes and agreements N/A $0.5 Isolagen entered into secured promissory notes and agreements with eight lenders to borrow $500,417 at an interest rate of 20% per annum (5/6)
Kamada Ltd. (Israel; TASE: KMDA; PK:KAMAF Private placement of common stock 2.6S $7 Kamada raised $7M through the private allocation of 2.6M shares to a group of investors that includes board Chairman Ralf Hahn and UDT Med Holdings LLC (5/4)
Kamada Ltd. (Israel; TASE: KMDA; PK:KAMAF) Private placement N/A $1.5 Kamada raised another $1.5M through a private placement with Meitav, an institutional investor in Israel (5/11)
Oncolytics Biotech Inc. (Canada; ONCY) Equity financing 3.45U $6 Oncolytics entered an agreement with Bolder Investment Partners Inc. to buy 3.45M units at $2 per unit for gross proceeds of $6M (5/1)
OncoMethylome Sciences SA (Belgium; BR:ONCOB) Warrant exercise 0.0245S €0.11
($0.156)
OncoMethylome raised $155,569 as a result of the exercise of warrants (5/29)
Oncothyreon Inc. (ONTY) Private placement of common stock and warrants 3.88S and W for 2.91S $11.1 Oncothyreon raised $11.1M through the sale (5/20)
PolyMedix Inc. (OTC BB:PYMX) Equity line facility N/A $10 PolyMedix entered into an agreement with Dutchess Equity Fund LP for up to $10M of financing through an equity line facility (5/21)
Rexahn Pharmaceuticals Inc. (AMEX:RNN) Private placement of common stock and warrants 2.9S and W for 5.6S $10 Rexahn sold the stock and warrants to a single institutional investor (5/20)
SemBioSys Genetics Inc. (Canada; TSX:SBS) Loan N/A $1.5 SemBioSys reached an agreement with AVAC Ltd.for a $1.5M loan, repayable within 18 months (5/4)
Spectrum Pharmaceuticals Inc. (SPPI) Registered direct offering 3.9S and W for 1.96S $20 Spectrum received commitments from Federated Kaufmann Fund and two other institutional investors; Rodman & Renshaw LLC acted as the exclusive placement agent (5/27)
Synairgen plc (UK; LSE:SNG) Private placement of common stock 29.5S £6.35
($10.2)
Synairgen raised $10.2M through institutional investors (5/29)
ThromboGenics NV (Belgium; BR:THR) Exercise of warrants N/A €3.1
($4.1)
ThromboGenics raised $4.1M through the exercise of warrants by its employees (5/7)
Unigene Laboratories Inc. (OTC BB:UGNE) Private placement 0.375S $5 Unigene drew down $5M under its agreement with Victory Park Management LLC in exchange for 375,000 shares (5/29)
Vernalis plc (UK; LSE:VER) Private placement 799S £22.1
($36.9)
Vernalis raised $36.9M offering 799M shares at 3 pence each, a 25.9% discount (5/5)
Vical Inc. (VICL) Registered direct offering 6.7S $20 Vical raised $15.4M in an offering of 6.7M shares of common stock and options to buy up to 3.3M additional shares (5/22); Vical received a commitment from Special Situations Funds to buy about $4.6M of securities on the same terms; it will sell 2M shares of common stock and option to buy up to 1M additional shares (5/26)
Vicor Technologies Inc. (OTC BB:VCRT) Private placement of 8% convertible notes N/A $0.74 Vicor raised $740,000 through the sale of notes due in 2011 (5/7)
XOMA Ltd. (XOMA) Private placement of units 11.8U $10 XOMA raised $10M through the sale of 11.8M units, each comprising one common share and a warrant to purchase half a common share (5/15)

Notes:
This chart does not include real estate or manufacturing plant financings, or debt deals done to replace existing debt.
# Unless otherwise indicated, shares are traded on the Nasdaq exchange; @ Refers to the date of the press release. ** Denotes the date the item ran in BioWorld International. Currency conversions are based on exchange rates at the time of the deal.
N/A = Not applicable; ND = Not disclosed.AMEX = American Stock Exchange; BR = Brussels Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; PK = Pink Sheets; TASE = Tel Aviv Stock Exchange; TSX = Toronto Stock Exchange.